Earnings Alerts

Beijing Wantai Biological Phar (603392) Earnings: 1Q Reports a Net Loss of 52.8M Yuan Amid 400.6M Revenue

  • Wantai Bio reported a net loss of 52.8 million yuan for the first quarter of 2025.
  • The company’s revenue for the same period was 400.6 million yuan.
  • Analyst recommendations for Wantai Bio stock currently include one “buy,” one “hold,” and one “sell.”

A look at Beijing Wantai Biological Phar Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth2
Resilience4
Momentum3
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Analysts at Smartkarma have assessed Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.’s long-term outlook using their Smart Scores system. With a score of 4 for Resilience, the company demonstrates strong capabilities to weather economic uncertainties and market volatility. This indicates a positive sign for investors looking for stability in their investments. Additionally, Beijing Wantai Biological Phar received a score of 3 for Momentum, suggesting that the company is showing consistent growth potential and performance in the market.

While Beijing Wantai Biological Phar scored a 2 in Value, Dividend, and Growth categories, indicating some room for improvement in these areas, the higher scores in Resilience and Momentum reflect optimistic signs for the company’s future prospects. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. specializes in manufacturing medical products such as diagnostic reagents, vaccines, and biochemical products, catering to the healthcare industry’s essential needs.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars